Amgen Q1 EPS Beats, Revenue Up 6%

Amgen reported adjusted EPS of $5.15, topping consensus $4.80 by $0.35.
Revenue reached $8.62 billion, slightly above $8.59 billion estimate and up 6% YoY from $8.15 billion in Q1 2025.
R&D expenses rose 16% YoY, driven by later‑stage programs including obesity candidate MariTide, while free cash flow grew to $1.5 billion.
Sixteen products posted double‑digit growth; Repatha sales jumped 34% to $876 million, UPLIZNA surged 188% to $262 million.